B of A Securities Rates Jazz Pharmaceuticals (JAZZ) buy
B of A Securities maintains a buy rating for Jazz Pharmaceuticals, setting a $307 price target, a 33.15% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B of A Securities rated Jazz Pharmaceuticals plc ($JAZZ) "buy" with a $307 price target on June 10, 2026.
Since the rating, $JAZZ is down 1.2% after 1 week, up 6.2% after 1 month and down 8.4% to date (from the $229.63 close on Jun 10, 2026).
JAZZ
Jazz Pharmaceuticals plc
Key Points
- B of A Securities reiterated its buy rating on Jazz Pharmaceuticals with a price target of $307.
- B of A Securities's $307 price target implies 33.15% upside from Jazz Pharmaceuticals plc's ($JAZZ) current $230.56 share price.
- Jazz Pharmaceuticals, trading at $230.56, has a market cap of $14.48 billion and a forward P/E of 9.0.
- Insiders at Jazz Pharmaceuticals made several planned sales, including EVP Neena Patil selling 1,200 shares.
Get $JAZZ trade alerts by text
We text you when insiders, Congress or big funds trade $JAZZ. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Jazz Pharmaceuticals plc alert may contain errors. Disclosures
B of A Securities reiterated its buy rating on Jazz Pharmaceuticals (NasdaqGS: JAZZ) on June 10, 2026, setting a price target of $307. Analyst Jason Gerberry expressed continued confidence in the stock, which recently traded around $230.56.
Jazz Pharmaceuticals plc Stock Down 4.2%
Shares of Jazz Pharmaceuticals are currently trading at $230.56 on the NasdaqGS. The company has a market cap of approximately $14.48 billion and a forward P/E ratio of about 9.0. Jazz's stock has a 52-week range between $105.00 and $243.32, with a 50-day moving average of $217.29 and a 200-day moving average of $173.04. The company maintains a current ratio of 2.04 and a quick ratio of 1.65, with a debt-to-equity ratio of 119.52.
$JAZZ price target
Jazz Pharmaceuticals plc daily closes and this analyst's $307 target. Not advice.
Recent Earnings
In its most recent financial report, Jazz Pharmaceuticals reported revenue of approximately $4.44 billion, with a revenue growth rate of 19.1%. The company's net margin stood at 0.66%, while return on equity was 0.68%. Jazz is expected to announce its next earnings on May 5, 2026.
Insider Buying and Selling at Jazz Pharmaceuticals plc
Several insiders at Jazz Pharmaceuticals have made planned sales recently. On June 10, 2026, Neena Patil, EVP & Chief Legal Officer, sold 1,200 shares at an average price of $231.83. Earlier, on June 1, 2026, Bruce Cozadd sold 6,000 shares at $235.12 under a planned transaction.
Analysts Set New Price Targets
On June 10, 2026, B of A Securities maintained its buy rating on Jazz Pharmaceuticals with a price target of $307. Barclays also maintained a buy rating with a $253 target on May 27, 2026. UBS upgraded Jazz to a buy with a $307 target on May 19, 2026. Overall, the consensus among 19 analysts is a buy rating, with an average price target of $255.95.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, headquartered in Dublin, Ireland, is a global biopharmaceutical company. It focuses on developing and marketing pharmaceutical products for various medical conditions, including sleep disorders and cancer. Led by CEO Renee D. Gala, Jazz Pharmaceuticals employs around 2,890 people. Its key products include Xywav, Epidiolex, and Rylaze, among others.
Bottom Line
B of A Securities' reiteration of its buy rating on Jazz Pharmaceuticals underscores continued optimism for the company's future performance. With a solid market position and a diverse product portfolio, Jazz Pharmaceuticals remains a significant player in the biotechnology sector. Investors should note that analyst ratings are one of many factors to consider, and this 13F filing reflects data as of the reporting period.
Related Filing Alerts
Source: B of A Securities's rating change on $JAZZ (Jun 10, 2026). Written by software, not financial advice. How we make alerts